How much of CRISPR Therapeutics’ revenue comes from haram?

CRISPR earns its revenue from the following revenue sources:

  • Collaboration Revenue: 

CRISPR currently does not generate revenue from its therapeutic products, although it has many treatments in development for sickle cell disease, cancer, muscular dystrophy, cystic fibrosis, and diabetes.

CRISPR earns all of its revenue from collaboration agreements and research with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Nkarta, and Capsida Biotherapeutics.

  • Grant Revenue:

Includes revenue generated from contracts with not-for-profit organizations.

As of Q1, 2021, CRISPR’s revenue breakdown was as follows:

Practical Islamic Finance concludes:

None of CRISPR’s revenue comes from anything inherently haram.

Does CRISPR Therapeutics rely on interest to operate?

For the Trailing Twelve Months as of March 31, 2021:

Interest Income: $2,000,000

Total Revenue: $1,101,000

Interest Expense: $0

Total Expenses: $396,493,000

While CRISPR earned more income from interest than it did from normal revenue in recent months, Practical Islamic Finance does not consider this current snapshot in time of Crispr’s financials to be representative of Crispr’s normal operations or business model. After all, CRISPR’s treatments are currently in clinical trials. 

For a more accurate assessment of CRISPR’s normal operations we consider data from previous years as well.

In 2019, CRISPR earned $289,590,000 in revenue and an average of $83,607,000 in revenue over the last 4 years. 

Taking CRISPR’s average annual revenue from the past 4 years and Crispr’s interest income from the trailing twelve months, interest income contributes 2.39% of the company’s average annual total revenue. 

Practical Islamic Finance concludes:

Riba is used but not relied upon in CRISPR’s operations.

What is CRISPR Therapeutics Environmental, Social, and Governance (ESG) impact?

Environment

No notable environmental highlights.

Social

CRISPR Therapeutics has an above-average Glassdoor rating of 3.6 out of 5.0 from 16 current and previous employees compared to a 3.3 average for all other Glassdoor rated companies.

In addition, CRISPR’s research efforts further the advancement for curing diseases such as cancer, blindness, and Alzheimer’s disease.

Governance

No notable governance highlights.

Practical Islamic Finance concludes:

CRISPR Therapeutics has a net positive ESG impact.

Comfort Rating

CRISPR Therapeutics’ business, financial, and ESG reviews, Practical Islamic Finance rates CRISPR Therapeutics as:

Comfortable to invest in from a Halal perspective.

Sources

CRISPR THERAPEUTICS AG 10-K

CRISPR THERAPEUTICS AG 10-Q

CRISPR Therapeutics Reviews